Cerus

cerus.com

Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as Chikungunya, malaria and dengue.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

8th International Conference on Bio-Sensing Technology

Conference

Related News

BGN TECHNOLOGIES ANNOUNCES RESEARCH COLLABORATION AGREEMENT WITH ECOIBÉRIA IN THE FIELD OF PLASTIC RECYCLING BY BACTERIA

BGN Technologies | November 05, 2020

BGN Technologies, the technology transfer company of Ben-Gurion University of the Negev (BGU), announced today that it had signed a research collaboration agreement with ECOIBÉRIA in the field of plastic recycling by bacteria, based on research from the team of Prof. Ariel Kushmaro and Prof. Alex Sivan, both from the Laboratory of Environmental Biotechnology and Avram and Stella Goldstein-Goren Department of Biotechnology Engineering at BGU. Polyethylene terephthalate (PET) is the most ab...

CHARLES RIVER AND VALENCE DISCOVERY DECLARE STRATEGIC PARTNERSHIP TO PROVIDE AI-ENABLED DRUG DESIGN CAPABILITIES TO CLIENTS

Valence Discovery, Charles River | April 08, 2021

Charles River Laboratories International, Inc. and Valence Discovery today reported the arrangement of an essential association to give customers admittance to Valence's computerized reasoning stage for sub-atomic property expectation, generative science, and multiparameter improvement. Expanding on research done by Valence's establishing group at Mila, the world's biggest profound learning research organization, the Valence stage empowers the plan of little atom drug ...

MedTech

NOVIR ANNOUNCES THE EVOLUTION OF THEIR BUSINESS TO A MORE COMPREHENSIVE HEALTHCARE SOLUTIONS PROVIDER FOCUSED ON ADVANCING THE PRE-CARE PATHWAY

Businesswire | June 08, 2023

Novir, an emerging biotechnology company, focused on pioneering the pre-care pathway to better health, has announced today the launch of their refreshed brand, dedicated to showcasing the evolution Novir has taken from a COVID-19 testing and vaccination provider to a more comprehensive healthcare solution committed to advancing healthcare from sick-care to pre-care by offering affordable, accessible, and reliable screening solutions to anyone, anywhere, anytime. Since their ince...

INTERNATIONAL BIOTECHNOLOGY LOOKING TO THE LONG TERM RATHER THAN CORONA CURES

Investors Chronicle | April 30, 2020

Healthcare companies around the world are scrambling to produce drugs and vaccines to treat and immunise people against Covid-19. However, the managers of International Biotechnology Trust (IBT) are not necessarily investing in these companies as their share prices are volatile, shooting up on reports of possible treatments in development.For example, Carl Harald Janson, lead manager of International Biotechnology Trust, recently reduced the trust’s holding in Gilead Sciences (US:GIL...